NAGE

Niagen Bioscience, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture

70%

bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression

40%

bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback

60%

neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat

30%

Filing History

10-QMay 6, 2026

The Q1 2026 filing presents a company at a crossroads between strategic optimization and operational instability. The divestiture of the analytical segment and the resulting $4.8 million gain provided a temporary boost to net income, but the underlying core business is struggling with rising customer acquisition costs and a precarious supply chain. The shift toward e-commerce is a positive trend, yet it is offset by a worrying reversal in operating cash flow. Investors must weigh the potential of the pharmaceutical pipeline and the strength of the current cash balance against the looming risks of single-source dependency and unresolved legal challenges. The company's ability to transition from a niche supplement provider to a dominant longevity player depends on whether it can stabilize its cash flow and diversify its supply chain before its current liquidity cushion is eroded by legal costs or operational failures.